[Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].

Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw

Klinika Pediatrii, Oddział Endokrynologii Instytutu "Pomnik--Centrum Zdrowia Dziecka" w Warszawie, Warszawa.

Published: January 2007

The main method of treatment of adrenocortical tumours is surgery. The efficacy of the mitotane therapy is still controversial with many serious side effects of the therapy. Moreover, patients receiving mitotane should be carefully monitored for adrenal insufficiency and usually require long-term hormone replacement therapy. We present a rare case of normalisation of the contralateral adrenal function after long-term mitotane therapy as a post-surgical treatment of the adrenocortical tumour.

Download full-text PDF

Source

Publication Analysis

Top Keywords

mitotane therapy
12
treatment adrenocortical
12
contralateral adrenal
8
adrenal function
8
function long-term
8
long-term mitotane
8
therapy
5
[normalisation contralateral
4
mitotane
4
therapy girl
4

Similar Publications

Adjuvant radiation therapy improves outcome of patients with surgical resected adrenocortical carcinoma.

Endocrine

January 2025

Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

Purpose: Adrenocortical carcinoma (ACC) is a rare malignancy known for high rates of recurrence and poor prognosis. Previous studies revealed controversial roles of adjuvant radiation therapy (RT) in patient management. This study aimed to investigate the role of adjuvant RT in postoperative ACC patients.

View Article and Find Full Text PDF

Purpose: Adrenocortical carcinoma (ACC) is a rare, aggressive pediatric malignancy. Advanced ACC requires multimodal treatment, including surgery and systemic chemotherapy including cisplatin, etoposide, doxorubicin, and mitotane. This is associated with significant gastrointestinal toxicity, resulting in many patients being unable to complete scheduled therapy.

View Article and Find Full Text PDF

Advances in pharmacological treatment of Cushings disease.

Zhong Nan Da Xue Xue Bao Yi Xue Ban

July 2024

Department of Endocrinology &Metabolism, West China Hospital, Sichuan University, Chengdu 610041.

Cushing's disease is a rare endocrine disorder characterized by hypercortisolism. Chronic elevated cortisol levels can lead to dysfunction or complications in multiple organs of systems, including cardiovascular, glucose, and bone metabolism, severely impacting patients' quality of life and posing life-threatening risks. Surgery is the first-line treatment for Cushing's disease.

View Article and Find Full Text PDF

Adrenocortical carcinomas (ACCs) are rare and aggressive malignancies of adrenal cortex, associated with largely unknown mechanisms of biological development and poor prognosis. Currently, mitotane is the sole approved drug for treating advanced adrenocortical carcinomas (ACCs) and is being utilized more frequently as postoperative adjuvant therapy. Although it is understood that mitotane targets the adrenal cortex and disrupts steroid production, its precise mechanism of action requires further exploration.

View Article and Find Full Text PDF

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex that is associated with a poor prognosis. Developing effective treatment options for ACC is challenging owing to the current lack of representative preclinical models. This study addressed this limitation by developing and characterizing 3-dimensional (3D) cell cultures incorporating the ACC cell lines, MUC-1, HAC15, and H295R in a type I collagen matrix.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!